Clinical Trials Logo

Stomach Neoplasms clinical trials

View clinical trials related to Stomach Neoplasms.

Filter by:

NCT ID: NCT04221893 Recruiting - Clinical trials for Stage IV Colorectal Cancer AJCC v8

Radiation Therapy for the Treatment of Metastatic Gastrointestinal Cancers

Start date: August 7, 2020
Phase: N/A
Study type: Interventional

This phase II trial studies how well radiation therapy works for the treatment of gastrointestinal cancer that are spreading to other places in the body (metastatic). Radiation therapy uses high energy x-rays to kill cancer cells and shrink tumors. This trial is being done to determine if giving radiation therapy to patients who are being treated with immunotherapy and whose cancers are progressing (getting worse) can slow or stop the growth of their cancers. It may also help researchers determine if giving radiation therapy to one tumor can stimulate the immune system to attack other tumors in the body that are not targeted by the radiation therapy.

NCT ID: NCT04220827 Active, not recruiting - Clinical trials for Peritoneal Carcinomatosis

Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer

Start date: December 6, 2019
Phase: Phase 1
Study type: Interventional

This phase I trial studies the side effects and best dose of paclitaxel for the treatment of gastric or gastroesophageal cancer. Drugs used in chemotherapy, such as paclitaxel, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading.

NCT ID: NCT04219332 Active, not recruiting - Gastric Cancer Clinical Trials

Randomized Controlled Trial on Effect of Lymph Node Mapping by Indocyanine Green Via Submucosal or Subserosal Injection

Start date: December 31, 2019
Phase: Phase 3
Study type: Interventional

The purpose of this study was to evaluate whether submucosal or subserous injection of indocyanine green during laparoscopic lymphadenectomy for patients with gastric cancer was different. The patients with gastric adenocarcinoma (cT1-4a, N0/+, M0) were studied.

NCT ID: NCT04215861 Recruiting - Breast Cancer Clinical Trials

Clinical Study on Raman Spectra of Blood, Saliva and Urine in Patients With Cancer Treated by Modern Therapy

Start date: October 1, 2019
Phase:
Study type: Observational

Blood, saliva and urine samples of tumor patients on the day of admission and discharge were collected for Raman spectral analysis, which provided exploration for the prediction of efficacy, follow-up and prognosis according to the variation characteristics of Raman spectral.

NCT ID: NCT04214990 Recruiting - Gastric Cancer Clinical Trials

Aspirin Use for Gastric Cancer Prevention in the Early Gastric Cancer Patients

EASTERN
Start date: February 15, 2020
Phase: Phase 3
Study type: Interventional

This study aimed to investigate the effect of low-dose (100 mg) asprin on the prevention of gastric cancer in the early gastric cancer patients with negative H. pylori status who underwent endoscopic submucosal dissection.

NCT ID: NCT04213794 Recruiting - Clinical trials for Recurrent Ovarian Carcinoma

Heated Intra-peritoneal Chemotherapy With Doxorubicin and Cisplatin for Abdominal for Pelvic Tumors in Pediatric Patients

TOASTIT
Start date: November 8, 2019
Phase: Early Phase 1
Study type: Interventional

This early phase I trial studies how well heated intra-peritoneal chemotherapy with doxorubicin and cisplatin work for the treatment of abdominal or pelvic tumors that can be removed by surgery (resectable), does not respond to treatment (refractory), or has come back (recurrent). Heated intra-peritoneal chemotherapy is a procedure performed in combination with abdominal surgery for cancer that has spread to the abdomen. It involves the infusion of a heated chemotherapy solution that circulates into the abdominal cavity. Chemotherapy drugs, such as doxorubicin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Heating a chemotherapy solution and infusing it directly into the abdomen may kill more cells.

NCT ID: NCT04209933 Completed - Gastric Cancer Clinical Trials

Helicobacter Pylori Eradication With Different Bismuth Quadruple Therapies

Start date: May 25, 2020
Phase: Phase 4
Study type: Interventional

This study aims to compare efficacy and safety of bismuth-containing quadruple therapy(with rabeprazole amoxicillin clarithromycin)of different kinds of bismuth(Bismuth potassium citrate, pectin bismuth capsules, pectin bismuth particles)in H. pylori first-line eradication. It is hypothesized that different bismuth containing quadruple therapies have comparable eradication efficacy and safety. Patients with confirmed H. pylori positive status will be randomized to one of the treatments described above. At week 2and 6 follow-up visits, a urea breath test(UBT) will be performed to confirm eradication.

NCT ID: NCT04208958 Completed - Colorectal Cancer Clinical Trials

Study of VE800 and Nivolumab in Patients With Selected Types of Advanced or Metastatic Cancer

ConsortiumIO
Start date: January 23, 2020
Phase: Phase 1/Phase 2
Study type: Interventional

This study evaluated the safety and efficacy of VE800 in combination with nivolumab in patients with selected types of advanced or metastatic cancer

NCT ID: NCT04205097 Completed - Gastric Cancer Clinical Trials

Deep vs Moderate Neuromuscular Blocks on Remifentanil for Laparoscopic Gastrectomy

Start date: December 23, 2019
Phase: N/A
Study type: Interventional

The primary purpose is to compare the remifentanil requirements in deep vs moderate neuromuscular blocks during the surgical pleth index -guided anesthesia in patients undergoing laparoscopic gastrectomy.

NCT ID: NCT04198766 Recruiting - Clinical trials for Non-Small Cell Lung Cancer

Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)

Start date: December 10, 2019
Phase: Phase 1
Study type: Interventional

This is a Phase 1/2, open-label, non-randomized, 4-part Phase 1 trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda).